News Center

On February 3, 2025, the Medlab Middle East opened at the Dubai World Trade Center. Lifotronic featured its complete range of in-vitro diagnostic platform solutions at booth Z4, H20, presenting multidimensional technological achievements to the audience.
 
Full Range of ECLIA Products Make a Strong Debut, Setting New Standards for Testing
 
At this exhibition, Lifotronic proudly showcased its full range of ECLIA products, covering the testing needs of large, medium, and small laboratories. A highlight was the eCL9000 high-speed immunoassay analyzer, which has been available on international markets since 2024. Thanks to its outstanding performance and technical advantages, it has gained wide recognition from customers. This exhibition focused on the integrated solution of the eCL9000, further meeting high-end customers' needs for throughput.
 
As the successor to the eCL9000, the eCL8600 continues with the same advanced technology platform, capable of 200 tests per hour, with 30 reagent positions and 80 sample positions. The eCL8600 adopts a dual cleaning system, combining swab and waterfall cleaning techniques, significantly reducing cross-contamination. It also employs an advanced degassing system to eliminate bubbles, enhancing instrument stability and reliability. Additionally, its multi-magnetic separation structure greatly improves detection sensitivity, ensuring the accuracy of test results.

 
 The reagents are compatible across different models, maintaining consistent quality. The accompanying emergency tests for cardiac biomarkers, tumor markers, etc., provide results in just 9 minutes, significantly reducing turnaround time and providing valuable diagnostic and treatment opportunities for doctors and patients. Notably, the newly launched second-generation sandwich 25-OH-VD assay, traceable to the international standard reference material SRM 2972b, shows a high correlation of 0.9827 with the gold-standard mass spectrometry results, proving its reliability in Vitamin D detection.
 
Innovative HPLC Solutions for Accurate Diabetes Monitoring and Thalassemia Screening
 
Lifotronic has been committed to the innovation and optimization of HPLC analyzers, launching a series of advanced HPLC instruments aimed at providing comprehensive solutions for diabetes management and thalassemia screening. Addressing medical challenges in the Middle East, particularly diseases like thalassemia and diabetes, Lifotronic introduced the high-end H100 model, which features a 96s variation mode for accurate hemoglobin A1c (A1c) testing, capable of identifying various hemoglobin variants such as E/D/S/C/J. This mode not only provides accurate A1c results but also detects potential variant diseases, offering more comprehensive diagnostic information for clinicians. Furthermore, the H100 supports one-click switching without the need for reagent or chromatography column changes, enabling rapid thalassemia testing in just 350 seconds, significantly improving clinical testing convenience and efficiency.
 
At the exhibition, Lifotronic also presented an innovative whole-blood integrated (HPLC+CBC) solution. This highly integrated solution not only greatly enhances laboratory productivity and testing efficiency but also meets international requirements for optimizing and managing laboratory space.

 
 Through these innovative products and solutions, Lifotronic further solidified its leadership position in the high-pressure liquid chromatography field, providing more accurate and efficient solutions to meet the medical needs of the Middle East and other regions.

 With the support of the "Belt and Road" initiative, Lifotronic, as one of China's leading healthcare representatives, will continue to showcase the new image and unique advantages of Chinese brands on the global stage. The company is committed to advancing innovative healthcare solutions and bringing cutting-edge technologies to the world. Lifotronic adheres to the philosophy of open cooperation and win-win development, continuously breaking through barriers and collaborating with global partners to drive the health industry forward and benefit global populations.